CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients

Capital Medical University

Status and phase: Unknown; Phase 2

Conditions: Acute Lymphoblastic Leukemia

Treatments: Biological: CD19 hsCAR-T

Study type: Interventional

Funder types: Other

Identifiers

NCT03902197

CD19hsCAR20190401

Details and patient eligibility

About

This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T) in refractory/relapsed CD19+ B-ALL leukemia patients who have no available curative treatment options, have a limited prognosis with currently available treatments, and were previously treated with a B cell directed cell therapy.

Full description

CD19+ B-ALL patients who have relapsed after murine-based CD19 CAR-T (CD19mCAR-T) treatment and/or have limited clinical response to CD19mCAR-T will be enrolled to receive CD19 hsCAR-T treatment.

Enrollment: 50 estimated patients

Sex: All

Ages: 1 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects with refractory/relapse B-cell ALL with no available curative treatment options (such as autologous or allogeneic SCT);

2. Subjects previously treated with B cell-directed engineered cell therapy are eligible if they meet the following criteria:

   1. relapsed and/or MRD-positive after prior cell therapy;
   2. partial response to prior cell therapy;
   3. Clinical and laboratory data are available;

3. Documented CD19 expression after previous B cell-directed therapies;

4. Aged 1 to 75 years;

5. KPS>40；

6. At least 2 weeks or 5 drug half-lives, whichever is shorter must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy;

7. Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and throughout the last follow-up visit;

8. Subjects with relapsed disease after prior allogeneic SCT (myeloablative or non-myeloablative) will be eligible if the patients do not present with active GVHD and are not undergoing immunosuppressive regimes;

9. Patients with CNS3 (WCB ≥5/mL in CSF with presence of lymphoblasts) disease will be eligible if the CNS disease is responsive to therapy;

10. Participation in the clinical trials should be voluntary with signed informed consent.

Exclusion criteria

1. Patients with hypervolemia (white blood cell count> 50 x 10^9 / L) or rapidly progressive disease that in the estimation of the investigators and sponsors would compromise the patient's ability to complete the study;
2. History of melanoma skin cancer or other primary tumors (eg, cervical cancer, bladder cancer, breast cancer) (except for those with 3 years or longer of cure);
3. Patients with fungal, bacterial, viral, or other uncontrollable infections or infections requiring Level 4 isolation (UTI or inoculation assays may be performed if necessary);
4. Patients with positive results for HIV, HBV, HCV tests;
5. With CNS disorders such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or autoimmune disease with CNS involvement;
6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac diseases within 12 months of enrollment, or with cardiac atrial or cardiac ventricular lymphoma;
7. Patients that are receiving anticoagulant therapy or have ever coagulation disorders;
8. Any medical condition that in the judgment of the sponsors/investigators is likely to interfere with assessment of safety or efficacy of study;
9. History of severe immediate hypersensitivity reaction to any of the agents used in this study;
10. Female patients who are pregnant or breastfeeding;
11. Feasibility assessment during screening demonstrates <30% transduction of target lymphocytes, or insufficient expansion (< 5-fold) in response to CD3/CD28 co-stimulation;
12. Patients with any uncontrolled diseases that are unsuitable for enrollment;
13. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity;
14. Any situation that is considered to potentially increase the risk of the subject or interfere with the outcome of the study;
15. Patients who have been enrolled in other clinical studies.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

CD19 hsCAR-T

Experimental group

Description:

This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR

Treatment:

Biological: CD19 hsCAR-T